This training will generate a sense of confidence in the performance of medical practice, which will help you grow both personally and professionally"

Cancer patients often present pathologies associated with the oncological process that require care. On the other hand, approaches to cancer patients are often aggressive and can affect other systems, which in the case of frail patients is a major problem in managing risk in therapeutic choices.

The heart is undoubtedly one of the organs most affected by systemic cancer treatments, and considering the importance of its functioning, it becomes an area of study that requires rigor, depth and timeliness.

Cardiological effects are routinely present in the side effects of most treatments for the oncology patient. The management of the medication, as well as of other therapeutic options, is fundamental in the adjustment of the appropriate dosage for medical praxis. Being up to date on the details of cardiac risk management in this type of patient is a fundamental skill for the physician to possess when dealing with the patient and his or her symptoms.

This program is designed to facilitate the specialist's updating process, so that he/she can include in the clinical practice of their patients all the innovations and the latest knowledge about oncological therapeutics.

Update your knowledge with the postgraduate diploma program in Cardiotoxicity, Mechanisms and Early Detection"

The postgraduate diploma in Cardiotoxicity, Mechanisms and Early Detection contains the most complete and up to date scientific program on the market. The most important features of the program include:

• Development of case studies presented by experts in Cardiotoxicity, Mechanisms and Early Detection. The graphic, schematic, and eminently practical contents with which they are created provide scientific and practical information on the disciplines that are essential for professional practice
• Developments on the cardiotoxic effect of oncologic therapies and cardiac risk assessment
• It contains practical exercises where the self-evaluation process can be carried out to improve learning
• With special emphasis on innovative methodologies in therapeutic risk assessment
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This postgraduate diploma may be the best investment you can make in the selection of a refresher program for two reasons: in addition to updating your knowledge in Cardiotoxicity, Mechanisms and Early Detection, you will obtain an postgraduate diploma certificate from TECH Technological University"

Its teaching staff includes professionals in the field of cardiotoxic effects of oncological therapies and risk assessment, who bring to this training the experience of their work, as well as renowned specialists belonging to reference societies and prestigious universities.

The multimedia content developed with the latest educational technology will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive training program to train in real situations.

Its teaching staff includes professionals in the field of cardiotoxic effects of oncological therapies and risk assessment, who bring to this training the experience of their work, as well as renowned specialists belonging to reference societies and prestigious universities. To this end, the student will be assisted by a novel interactive video system developed by recognized experts in the field of cardiotoxic effects of oncological therapies and risk assessment, with extensive teaching experience.

Increase your decision-making confidence by updating your knowledge through this specialist course"

Seize the opportunity to learn about the latest advances in addressing the cardiotoxic effects of oncology therapies and risk assessment, and improve the care of your patients"

The Postgraduate Cardiotoxicity, Mechanisms and Early Detection is aimed at facilitating the actions of the physician dedicated to the treatment of oncological pathology, in which it is necessary to accurately interpret the toxic effects of possible occurrence and assess the cardiological risks inherent to the disease process.

This postgraduate diploma is designed for you to update your knowledge in Cardiotoxicity, Mechanisms and Early Detection, with the use of the latest educational technology, to contribute with quality and safety to decision making"

General Objective

• Update the knowledge of the specialist Cardiologist, Oncologist and Hematologist in the field of Cardio-Oncology
• Promote work strategies based on a comprehensive approach to the patient as a standard model for achieving excellent care
• Encourage the acquisition of technical skills and abilities, through a powerful audio-visual system, and the possibility of development through online simulation workshops and/or specific training
• Encourage professional stimulus through continuing education and research

Specific Objectives

• Know the epidemiological significance of cancer
  Know the clinical and epidemiological significance of cardiac toxicity
• Identify the epidemiological significance of prevention and early detection of cardiotoxicity
• Learn the objectives of the Cardio-Oncology Units
• Know the structure and organization of the Cardio-Oncology Units
• Define the concept of cardiotoxicity
• Learn the types of cardiotoxicity depending on the area affected
• Learn the types of cardiotoxicity according to the pathophysiological mechanism. Understand the molecular and tissue mechanisms leading to CT
• Recognize the cardiotoxic effects of thoracic radiotherapy
• Update the knowledge concerning the evolution of radiothoracic radiotherapy equipment and methods
• Explain the factors influencing acute and chronic radioinduced cardiotoxicity
• Recognize chemotherapeutic drugs implicated in cardiotoxicity
•  Analyze the cardiotoxic effects of anthracyclines
• Explain the cardiotoxic effects of anti-tubulins
• Explain the cardiotoxic effects of antimetabolites
• Explain the cardiotoxic effects of alkylating agents and other drugs that interact with DNA
• Analyze the cardiotoxic effects of biological agents, specifically trastuzumab-type monoclonal antibodies
• Become familiar with other potentially cardiotoxic biological agents
• Analyze the cardiotoxic effects of cell kinase inhibitors
• Be aware of other potentially cardiotoxic oncological treatments, such as antiangiogenic drugs, histone deacetylase inhibitors, differentiation and/or apoptosis inducers and hormone therapy
• Understand the individual susceptibility factors, both genetic and acquired, involved in the development of cardiac toxicity
• Be able to perform a comprehensive risk assessment of patients undergoing oncologic treatment
• Describe the monitoring required by patients during treatment for cardiotoxicity
• Identify biomarkers as a method used to detect cardiotoxicity early, especially troponins and natriuretic peptides
• Deepen the knowledge of echocardiography, with special attention to the "global longitudinal strain" technique as a marker for early detection of cardiac toxicity
• Know the role of cardiac magnetic resonance imaging in the early detection of cardiotoxicity
• Recognize the clinical relevance and mechanisms involved in the onset of ventricular dysfunction and heart failure secondary to cardiac toxicity
• Deepen our knowledge of myocardial involvement caused by anthracyclines
• Identify other chemotherapy drugs with the capacity to produce myocardial toxicity
• Deepen our knowledge of myocardial toxicity induced by monoclonal antibodies, especially tratuzumab
• Recognize the ability of therapies directed against new molecular targets (cellular kinase inhibitors) and proteosome inhibitors to produce ventricular dysfunction and heart failure
• Learn the effects of thoracic radiotherapy on the myocardium
• Improve knowledge in the clinical diagnosis of heart failure associated with cardiotoxicity
• Acquire updated knowledge in the treatment of heart failure and ventricular dysfunction related to oncological treatments
• Know the importance of early detection of myocardial involvement due to cardiotoxicity
• Describe the appropriate action to be taken in the event of an increase in circulating biomarkers during oncologic treatment
• Describe the appropriate response to the appearance of "global longitudinal strain" alteration during oncological treatment
• Learn the monitoring strategy during treatment with anthracyclines
• Learn the monitoring strategy during treatment with monoclonal antibodies, especially trastuzumab
• Learn the monitoring strategy during treatment with cell kinase inhibitors
• Understand the potential causes and mechanisms of ischemic heart disease in the context of cardiac toxicity
• Identify patients at high risk of coronary artery disease
• Define the role of oncological treatments such as fluoropyrimidines in the development of ischemic heart disease
• Acquire updated knowledge on diagnostic methods for coronary artery disease related to cardiotoxic drugs
• Get up to date on the management of acute coronary syndrome in the context of oncologic treatment
• Learn the monitoring strategy in patients who have had coronary ischemia
• Know the clinical relevance of thoracic radiotherapy in the development of coronary artery disease and its mechanisms
• Recognize the risk factors for the development of ischemic heart disease in patients who have received thoracic radiotherapy